A new alphabet for COPD care: where xe2x80x9cExe2x80x9d stands for Espaxc3xb1a

[摘要] ExtractWe read with interest the editorial by Kerwin [1] on the management of chronic obstructive pulmonary disease (COPD). This editorial follows the publication of the AFFIRM trial showing the superior bronchodilating effects of a long-acting muscarinic antagonist (LAMA)/long-acting xcexb2-agonist (LABA) combination over an inhaled corticosteroid (ICS)/LABA combination in a head-to-head trial; although symptom-based outcomes were not different [2]. These findings replicate those of the FLAME trial showing non-inferiority between a LAMA/LABA over an ICS/LABA combination; although reductions in exacerbations were greater in the former [3]. We would like to endorse the view of Kerwin [1] and Vogelmeier etxc2xa0al. [4] that it is a good time to xe2x80x9crefine the paradigmatic GOLD classificationxe2x80x9d.

[学科分类] 呼吸医学